The Faculty of Tropical Medicine has provided a significant proportion of the biological, economic and clinical basis for the change in global antimalarial treatment recommendations to artemisinin combination treatments. We have been responsible for publishing 9.4% of all antimalarial trials since 1966, and enrolled 22% of all patients in such studies worldwide. Following a series of pharmacokinetic-pharmacodynamic (PK-PD) studies in severe malaria, and a pilot comparison, we conducted the largest ever trial in severe malaria, a multi-country, prospective study to compare mortality in patients treated with intravenous artesunate or intravenous or intravenous quinine. We have developed a mathematical-economic model of drug resistance, which has been influential in guiding international recommendations. Most recently, our attention has been focused on antimalarial drugs that can block malaria transmission effectively.